– SWITZERLAND, Lausanne – ARTIRIA Medical, an EPFL spin-off, and neurovascular start-up closed a CHF 3M Series A financing led by 4FO Venture Partners alongside investiere, the Zürcher Kantonal Bank, NEST pension fund, Venture Kick and business angels also participating.
The financing will bring the first product through clinical validation and regulatory approval.
“ We are pleased to have investors sharing our vision and a board of directors with significant medical device expertise to help us deliver it,” said Marc Boers, Founder and COO of ARTIRIA.
About Artiria Medical SA
Today the best option to treat stroke consists of employing the patient vascular system as an access route to deliver treatment in the brain. Although 410’000 such procedures are carried out every year, current interventional devices do not provide sufficient control to the surgeon resulting in an increased risk of complications, increased costs, and increased surgery duration. We developed a micro-actuated device allowing us to treat vascular diseases with unprecedented accuracy, effectiveness, and safety.
For more information: https://artiria-medical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.